Home > Back to Publisher > Report Information

Parallel Trade - US Lawmakers Allow Imported Prescriptions Drugs

Visiongain
June 21, 2007
143 Pages - SKU: VSG1534800

Abstract Table of Contents Related Reports

Countries covered: United States

"Parallel Trade acts as an important driving force for market integration where there are important differences in price between member states"

- European Commission Communication on the single market in pharmaceuticals

Parallel trade is on the verge of breaking its confines of the EU and diffusing into other global markets. This global practice is far from simple, and the loopholes that have made it possible refuse to close. Whether you think parallel trade is a benefit or a cost, the reality is that it is affecting the whole pharma industry on a wide scale. It started out a North-South divide but even this is changing. The European Commission and other trade regulation bodies won't protect the pharma companies pricing structures.

Although consumers may think that imported drugs into the US come from Canada, UK, or other Western European nations, it's impossible to definitively verify an imported drug's country of origin.

Do developing countries see parallel trade as a benefit for cheap drugs and if so will it remain a benefit?
This year how much will pharma companies' profits be threatened by parallel trade?
With individual drugs already being bought in Canada and Mexico will large scale parallel trade become a reality in the US as there are no price controls in place?
The US market is such an attractive market for parallel traders. How will the enlargement of the EU, to 27 affect parallel trade?

Patients, general practitioners, healthcare agencies and national governments are all benefiting from this gray market import. However, there are actual 'real' winners in this trade, parallel traders themselves. They gain the most benefit from such a trade, which is pure profit. On the other hand, pharma companies are blaming parallel trade, for huge losses in revenue, which in affect lowers innovation. Parallel trade is seen as a gateway for counterfeit drugs entering the supply chain.

"In the European Union, products pass freely from one member nation to another - through a system called 'parallel trade.' Consequently, drugs sold in England may actually have originated in a country with less rigorous safety standards, such as Cyprus or Latvia". Warwick News

The latest case of counterfeit drugs entering the UK supply chain was that of Eli Lilly's antipsychotic drug, Zyprexa and Sanofi-Aventis and Bristol Myers Squibb's Plavix. Three batches were recalled by the MHRA. Isn't this enough evidence that parallel trade is having a negative affect on the pharma industry? Find out by buying this report.

Does parallel trade diminish the quality and safety of drugs? Isn't repackaging a great issue when it comes to parallel trade? Isn't the Internet is a great medium for a form of parallel trade? Many important questions that need answers.

Why You Must Buy This Report:

This 130+ paged report features key figures, including graphs and charts, important tables, news, insights, the latest developments in the parallel trade market with up-to-date analysis.

This report will give you the understanding you require to gain that competitive edge in the parallel trade market. This controversial practice is a hot topic in the pharma industry. Therefore, it is vital that the latest parallel trade report is brought without fail.

With in depth analysis of key markets, and the latest information on parallel trade, this report is vital to grasp an understanding of parallel trade.

Key questions that this report answers: Why aren't regulatory bodies protecting pharma companies from parallel trade?
What are the affects of parallel trade on each segment of the market?
Is it possible for pharma companies to protect themselves legally from?
What price link can pharma companies establish that will halt parallel trade without reducing profits further?
What liability do pharma companies face through repackaging when aligned with parallel trade?
How can big pharma use the internet to combat parallel trade?
How does parallel trade (re-importation) affect the US and Canada?
Unique benefits to you when you order this report:

You can access your report whichever country you are in without using hard drive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Full searchable report when you buy the company or corporate editions
Copies can be printed off as many times as you want for offline reading
Packed with charts, analysis, figures, graphs and tables.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Additional Information

List of Companies
Abacist Pharma
Abit Express
ACA Mueller
Acadic
Ace Pharma
Actipart
Alpha Med
Apothekamed
Arzneim Pharm
Beragena
Bestphago
Boehringer Ingelheim
Bios
Bristol Myers Squibb
Cancernova
Cocept Pharma
Diaprax
Doc Pharm
Ecowest
Eli Lilly
Farlic
Gerke Pharma
Gpp Pharma
Gruenwald
GSK
Holmsland
Isopharm
IPM
Kern
Kurz
Logimed
Lexon UK
Maximed
Maxi Pharma
Medartuum
Medi Spezial
Merck
Mevita
Naturprod
Novartis
Necessity Supplies
Omna Laek
Opti Arzeni
Parallel PH
Pfizer
Pharmel
Pharmpole
Pharm Dett
Qdoxx
Rehaforum
Sanofi Aventis
Servo Pharma
Sigma
Swingward and Doewlhurst
Trans Euro Med
Waymade
Werner
Western Pharma

Chapter 1. Executive Summary: Parallel Trade, Benefiting or Breaking the Pharma Industry?
Chapter 2. Parallel Trade in Global Pharmaceutical Industry: 2.1 What is Parallel Trade?; 2.2 Effects of Parallel Trade
Chapter 3. Legal Aspects of Parallel Trade: 3.1 Exhaustion of Rights; 3.2 Intellectual Property Rights; 3.3 Compulsory Licensing
Chapter 4. Price is the Principal Driver of Parallel Trade: 4.1 Pricing in Pharma; 4.2 Price Convergence; 4.3 Price Differential; 4.4 Pricing Control; 4.5 Price Limiting
Chapter 5. Parallel Trade in US and Canada: 5.1 Regulations in the US and Canada; 5.2 Medicare Act Reducing Reliance on Cheaper Drugs from Canada; 5.3 Safe Drugs are Only Imported from Canada; 5.4 FDA's Approach to Personal Importation; 5.5 The Future of Re-importation; 5.6 Differences in Pricing between the US and Canada; 5.7 Patented Drugs are Found to be Cheaper in Canada than in US; 5.8 US Generic Drugs Cost Less than Canadian Drugs
Chapter 6. Parallel Trade in Europe: 6.1 Parallel Trade Predominantly a European Activity; 6.2 Drug Prices in the EU; 6.3 UK - One of the largest Importers of Parallel Trade; 6.4 Germany; 6.5 France; 6.6 Spain; 6.7 Sweden; 6.8 Norway; 6.9 The Netherlands; 6.10 Denmark; 6.11 Parallel Exporting Countries; 6.12 GSK Wins Long Battle; 6.13 EU Enlargement; 6.14 Limitations to Growth
Chapter 7. The Role of the Internet in Parallel Trade: 7.1 Internet Usage is Immense; 7.2 Online Purchasing of Drugs; 7.3 Verified Internet Pharmacy Practice Sites (VIPPS); 7.4 Regulations for International Sites; 7.5 Canadian Internet Pharmacies; 7.6 Rogue Internet Pharmacies; 7.7 Operation Cyber Chase - A Year Long Investigation; 7.8 Online Pharmacies: Good or Bad?
Chapter 8. Counterfeiting is a Major Threat: 8.1 An Immense Concern Due to Counterfeiting; 8.2 Prevalence of Counterfeiting; 8.3 PSI - Will it help?; 8.4 Global Reports of Counterfeit Medicines; 8.5 Counterfeit Lipitor Dispersed through the UK Supply Chain
Chapter 9. The Issue of Repackaging: 9.1 The Repackaging of Pharmaceuticals is an Important Aspect of Parallel Trade; 9.2 Different Types of Packaging; 9.3 What a Package Must Do; 9.4 The EU Angle on Repackaging; 9.5 FDA's Approach to Repackaging; 9.6 Legal Case of Repackaging; 9.7 Repackaging Affects Quality
Chapter 10. Arguments for Parallel Trade: 10.1 York Study Did Show Healthcare Costs to be Reduced by Small Amounts; 10.2 Swedish Study Confirms Price Competitiveness in Parallel Trading of Drugs; 10.3 University of Southern Denmark Agrees with York Methodology; 10.4 EU Price Convergence Unlikely; 10.5 The British Association of European Pharmaceutical Distributors Aim to Deliver Value
Chapter 11. Arguments Against Parallel Trade: 11.1 Manufacturing Pharmaceutical companies Argument against Parallel Trade; 11.2 The Right to Maximise Returns; 11.3 LSE Report Showed Negligible Savings
Chapter 12. Parallel Trade: Double Edged Sword: 12.1 Benefits of Parallel Trade; 12.2 The Costs of Parallel Trade; 12.3 Global Growth of Parallel Trade; 12.4 The Future
List of Tables: Table 2.1 R&D Expenditure in the UK ($m); Table 4.1 Comparative Drug Prices in Selected Developed Countries; Table 4.2 All Factors that Influence Drug Prices; Table 4.3 Pricing Differentials for Leading Drugs (30 day supply); Table 4.4 Another Example of Differential Pricing (price per pill); Table 4.5 Advantages and Disadvantages of Single European Price; Table 5.1 Difference in Pricing of Selected Drugs; Table 5.2 U.S./Canadian Price Comparisons; Table 5.3 Price Per Standard Unit in the US Compared to Canada; Table 5.4 Price Per Standard Unit of Lipitor in the US and Canada; Table 5.5 Price Difference in Selected Generics; Table 6.1 Key Financials for the EU Pharmaceutical Industry ($m), 1990-2005; Table 6.2 EU Pharmaceutical Trade Balances ($m); Table 6.3 Price Per Standard Unit in EU States; Table 6.4 Price Per Standard Unit of Lipitor in EU States; Table 6.5 NHS Saving Compared to Parallel Importers' Profit; Table 6.6 UK Parallel Distributors; Table 6.7 German Parallel Importers; Table 6.8 Swedish Parallel Traders; Table 6.9 Norwegian Parallel Importers; Table 7.1 Internet Usage World Wide; Table 7.2 Top 20 Countries in Regards to Internet Usage; Table 7.3 World Online Drug Market; Table 7.4 US Agencies and their Authorities; Table 7.5 Differences between Rogue and Quality Sites; Table 8.1 Top Ranked Countries where Counterfeits were Seized/Discovered; Table 10.1 Estimated Total Direct Savings from Parallel Trade in 2002; Table 10.2 Estimated Direct Savings in 2004
List of Graphs: Graph 1.1 Global R&D Expenditure and NME output; Graph 4.1 Incidents in Europe; Graph 5.1 World Internet Usage; Graph 5.2 Top 20 Internet Usage Countries; Graph 5.3 World Online Drug Market ($bn); Graph 7.1 European Parallel Trade; Graph 7.2 EU Pharma Trade Balances; Graph 7.3 Share of Parallel Imports in Pharmacy Market Sales (%); Graph 7.4 Estimated Share of Parallel Imports in Pharmacy Market Sales (%), 2007
List of Figures: Figure 1.1 Parallel Trading; Figure 3.1 Cost of Production; Figure 3.2 Inelastic Market

More United States Prescription Drugs Reports

2012 Healthcare Business Market Research Handbook by Richard K. Miller & Associates
The 2012 Healthcare Business Market Research Handbook presents a comprehensive analysis of the $2.8 trillion U.S. healthcare marketplace with the most recent statistics and data ...

Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report by IBISWorld
Brand Name Pharmaceutical Manufacturing in the US Prescription for growth With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience ...

Analysis of the United States Contract Manufacturing Outsourcing Market by Frost & Sullivan
Contract manufacturing outsourcing (CMO) companies provide independent manufacturing services for pharmaceutical and biotechnological markets. This study covers the U.S. commercial manufacturing and packaging of pharmaceutical ...

United States Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Economics and politics are increasingly exerting an influence on the US pharmaceuticalmarket. This is in stark contrast to the late 1990s and early ...

The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment by AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “The US Pharmaceutical Market Outlook to 2015 – Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

Parallel Trade - US Lawmakers Allow Imported Prescriptions Drugs

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service